Get started
Author

Michiko Nonogi

Observed name: MICHIKO NONOGI
Observed institution: Tokushima Red Cross Hospital
ORCID: 0000-0002-8337-4846
Observed ORCID: 0000-0002-8337-4846
OpenAlex ID: A5080940798
Usefulness of neutrophil‐to‐lymphocyte ratio in predicting progression and survival outcomes after atezolizumab–bevacizumab treatment for hepatocellular carcinoma
2022 · Hironori Ochi, Masayuki Kurosaki, et al. · Hepatology Research · 49
PDF
Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group
2023 · Shintaro Takaki, Masayuki Kurosaki, et al. · Investigational New Drugs · 21
Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab
2022 · Nobuharu Tamaki, Toshifumi Tada, et al. · Investigational New Drugs · 17
Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma
2024 · Nami Mori, Nobuharu Tamaki, et al. · Investigational New Drugs · 15
Viral eradication reduces all‐cause mortality in patients with chronic hepatitis C virus infection who had received direct‐acting antiviral therapy
2024 · Toshifumi Tada, Masayuki Kurosaki, et al. · Liver International · 12
PDF
Change in Liver Function in Durvalumab Plus Tremelimumab Treatment for Unresectable Hepatocellular Carcinoma
2024 · NOBUHARU TAMAKI, NAMI MORI, et al. · Anticancer Research · 9
Pemafibrate improves liver biochemistry and GLOBE scores in patients with primary biliary cholangitis: Nationwide, multicenter study by the Japanese Red Cross Liver Study Group
2025 · Keiji Tsuji, Nobuharu Tamaki, et al. · Hepatology Research · 8
Effect of Direct‐Acting Antivirals on Prognosis in Older Patients With Hepatitis C Virus‐Related Hepatocellular Carcinoma After Curative Therapy: A Retrospective Study by the Red Cross Liver Study Group in Japan
2026 · Hironori Ochi, Masayuki Kurosaki, et al. · Hepatology Research · 4
Effect of Pemafibrate on Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Nationwide Multicenter Study
2025 · Yasuyuki Komiyama, Nobuharu Tamaki, et al. · JGH Open · 4
PDF
Effect of Proteinuria Before Lenvatinib Administration on Treatment Response After Atezolizumab Bevacizumab Combination Therapy
2025 · Hironori Ochi, Masayuki Kurosaki, et al. · JGH Open · 2
PDF
Sofosbuvir/Velpatasvir in Chronic Hepatitis C, Compensated and Decompensated Cirrhosis, and Retreatment Settings
2026 · Hitomi Takada, Nobuharu Tamaki, et al. · Internal Medicine
PDF
Works count: 11
Citation count: 141
H-index: 7
I10-index: 5
Year
Topic
Type